Good morning, everyone, and how are you today? We are just fine, thank you, especially as some welcome sunlight emerges over the soggy Pharmalot campus. As usual, we are proceeding apace with cups of stimulation and a long to-do list at hand. We have an extra treat for you at 12 p.m. ET today, as we will join Rachel Sachs in a STAT Plus chat to discuss the new PhRMA membership criteria (you can sign up here). Meanwhile, there is much to keep us busy. No doubt, you can relate. On that note, here are some tidbits for you. Have a grand day and keep in touch …
Following delays caused by manufacturing issues, Regeneron Pharmaceuticals and Sanofi finally won Food and Drug Administration for Kevzara to treat moderately to severely active rheumatoid arthritis in adults. The companies set a $39,000 list price, which is about 30 percent lower than rival medicines and “may secure favorable formulary positioning,” Baird analyst Brian Skorney predicts.
About the Author Reprints
